The objective of this study was to evaluate the effect of sorafenib on the outcomes of patients with acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: A total of 144 patients with FLT3-ITD AML undergoing allo-HSCT between January 2012 and December 2015 were enrolled in this study. Depending on whether they were receiving sorafenib before transplantation or sorafenib maintenance after transplantation, patients were divided into 4 groups: patients receiving sorafenib before transplantation (group A; n 5 36), patients receiving sorafenib after transplantation (group B; n 5 32), patients receiving sorafenib both before and after transplantation (group C; n 5 26), and patients receiving sorafenib neither before nor after transplantation (group D; n 5 50). Outcomes were compared among these groups. RESULTS: The 3-year relapse rates were 22.2%, 18.8%, 15.8%, and 46.1% for groups A, B, C, and D, respectively (P 5 .006). The 3-year overall survival (OS) rates were 74.9%, 78.1%, 84.6%, and 50.9%, respectively (P 5 .023), and the 3-year leukemia-free survival (LFS) rates were 69.4%, 78.1%, 80.4%, and 34.8%, respectively (P < .001). The relapse rate was higher and the LFS was shorter in group D versus groups A, B, and C. The OS in group D was shorter than the OS in group C but was similar to the OS in groups A and B. A multivariate analysis revealed that sorafenib before transplantation, sorafenib maintenance after transplantation, and their combined application were protective factors for a lower relapse rate (hazard ratios 2 Some studies have demonstrated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) could reduce the relapse rate and improve survival for AML patients with FLT3 mutations. 3, 4 Despite this, the rate of leukemia relapse remains high.
INTRODUCTION
FMS-like tyrosine kinase 3 (FLT3) gene mutations represent some of the most frequent genetic alterations in acute myeloid leukemia (AML) with an incidence of approximately 30%. 1 There are 2 categories of FLT3 mutations: internal tandem duplication (ITD) occurring in the juxtamembrane domain of the receptor (ie, FLT3-ITD; approximately 25%) and point mutations resulting in single amino acid substitutions in the activation loop of the tyrosine kinase domain (TKD; ie, FLT3-TKD; approximately 5%-7%). 1 Compared with AML patients with the FLT3 wild type, AML patients with FLT3 mutations have significantly shorter remissions and higher relapse rates. 2 Some studies have demonstrated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) could reduce the relapse rate and improve survival for AML patients with FLT3 mutations. 3, 4 Despite this, the rate of leukemia relapse remains high. 5, 6 FLT3-ITD mutations can render the tyrosine kinase constitutively active and thus result in chronic stimulation of downstream signaling pathways and abnormal proliferation of leukemic cells. 7 Sorafenib is a multikinase inhibitor that blocks various pathways potentially involved in the development of AML, such as FLT3-ITD, RAS/RAF, c-KIT, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor. 8 A growing body of clinical studies suggests that chemotherapy combined with sorafenib might promote longer remissions for patients with FLT3-ITD AML, especially for patients younger than 60 years. [9] [10] [11] Sorafenib maintenance after allo-HSCT has been proved to be safe for patients with FLT3-ITD AML, but whether it could improve survival remains uncertain. [12] [13] [14] In this study, we retrospectively evaluated the effect of sorafenib therapy on the outcomes of patients with FLT3-ITD AML undergoing allo-HSCT.
MATERIALS AND METHODS

Patients and Transplantation
This multicenter study was conducted from January 2012 to December 2015. Patients were included if they had FLT3-ITD AML and were undergoing allo-HSCT. The endpoint of the last follow-up was June 30, 2017. All living patients had a minimum follow-up of 18 months at the time of the analysis. Two myeloablative conditioning regimens were used: busulfan plus cyclophosphamide and modified busulfan plus cyclophosphamide. 15 Graftversus-host disease (GVHD) prophylaxis and infection prophylaxis were performed according to our previous description. 16, 17 The study was performed in accordance with the modified Declaration of Helsinki, and the protocol was approved by the respective ethical review boards before the study's initiation. All recipients, donors, and guardians provided written informed consent.
Mutation Analysis of FLT3-ITD and FLT3-TKD Genes
Genomic DNA was extracted from diagnostic marrow specimens with the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The mutation analysis of FLT3-ITD (exons 14 and 15) and FLT3-TKD (exon 20) genes was performed by polymerase chain reaction (PCR) and direct sequencing. 
Sorafenib Therapy
The indrawing criterion for sorafenib therapy (Nexavar; Bayer Pharma AG, Berlin, Germany) before transplantation was defined as more than 30 days of sorafenib administration before transplantation. Sorafenib therapy before transplantation included chemotherapy combined with sorafenib for induction, postremission maintenance treatment, or both. Sorafenib maintenance after transplantation was defined as the administration of sorafenib more than 30 days after transplantation for the prevention of relapse. Sorafenib was generally started from 30 to 180 days after transplantation if patients had hematopoietic reconstitution and no active GVHD. Once patients developed grade II or higher acute graft-versus-host disease (aGVHD), sorafenib was discontinued immediately. The initial dose of sorafenib therapy was generally 400 mg twice daily, and the dose was adjusted on the basis of suspected toxicity (dose range, 200-800 mg daily). Patients who received sorafenib salvage therapy after posttransplant relapse were not enrolled in the analysis of sorafenib maintenance after transplantation.
Evaluation, Definitions, and Statistics
This study was mainly focused on relapse, survival, GVHD, nonrelapse mortality (NRM), and adverse effects (AEs) of sorafenib therapy. Hematopoietic engraftment was defined as the first of 3 consecutive days with absolute neutrophil counts exceeding 0.5 3 10 9 /L and absolute platelet counts exceeding 20 3 10 9 /L without a platelet transfusion. Leukemia relapse was defined as bone marrow, extramedullary, or both according to common morphological criteria.
Comparisons of categorical variables were made by means of chi-square tests or Fisher exact tests. Differences between numerical variables were calculated by means of Mann-Whitney tests. We calculated cumulative incidences of relapse, NRM, and GVHD by accounting for competing risks, with death due to relapse treated as a competing event to calculate NRM and with death due to other causes treated as a competing risk for GVHD and relapse. Overall survival (OS) and leukemia-free survival (LFS) were estimated with the Kaplan-Meier method and were compared with the log-rank test. Multivariate analyses were performed with a Cox proportional hazards model. P < .05 was considered significant. SPSS 19.0 (SPSS, Inc, Chicago, Illinois) and R version 3.3.0 (R Development Core Team, Vienna, Austria) were used for all data analysis.
RESULTS
Patients' Clinical and Transplant Characteristics
A total of 144 consecutive patients with FLT3-ITD AML undergoing allo-HSCT were enrolled in this study; they included 65 receiving human leukocyte antigen-matched sibling donor transplants, 65 receiving human leukocyte antigen-haploidentical related donor transplants, and 14 receiving human leukocyte antigen-matched unrelated donor transplants ( Table 1 ). The median age at the time of transplantation was 35 years (range, 14-57 years); there were 63 females and 81 males. One hundred eleven patients were in complete remission (CR), 12 were in partial remission (PR), and 21 were in nonremission (NR) at the time of transplantation.
Engraftment and Disease Response
Except for 1 patient who was in persistent NR after transplantation, all the patients achieved hematopoietic reconstitution (n 5 143). The median times to neutrophil and platelet engraftment were 13 (range, 10-23 days) and 17 days (range, 9-125 days), respectively. Of the 33 non-CR patients at the time of transplantation, 32 had achieved a CR on day 130 after transplantation. The 1 patient in persistent NR died of leukemia progression on day 195 after transplantation.
Sorafenib Therapy
A total of 113 patients experienced 150 episodes of sorafenib therapy; they included 77 patients with 1 episode, 35 with 2 episodes, and 1 with 3 episodes of sorafenib therapy. As for the 150 episodes of sorafenib therapy, sorafenib was used before transplantation in 62 patients, as maintenance after transplantation in 58 patients, and as salvage therapy after posttransplant relapse in 30 patients. Of the 62 patients receiving sorafenib before transplantation, 29 received chemotherapy combined with sorafenib as initial induction and postremission maintenance, 12 received it as reinduction after relapse and postremission maintenance, and 21 received it as postremission maintenance alone. The median time of sorafenib therapy before transplantation was 89 days (range, 35-207 days). Twenty patients achieved a CR and 5 achieved a PR among the 29 patients receiving sorafenib as initial induction. Of the 12 patients receiving sorafenib as reinduction, 7 achieved a CR, and 3 achieved a PR. The CR rate for sorafenib therapy before transplantation was 65.9% (27 of 41) for untreated and refractory relapsed AML with FLT3-ITD.
Among the 58 patients who received sorafenib as maintenance after transplantation, sorafenib was initiated at a median of 30 days (range, 30-121 days) after transplantation, and the median time of sorafenib maintenance after transplantation was 146 days (range, 51-240 days).
Depending on whether they were receiving sorafenib before transplantation or sorafenib maintenance after transplantation, patients were divided into 4 groups: patients receiving sorafenib before transplantation (group A; n 5 36), patients receiving sorafenib maintenance after transplantation (group B; n 5 32), patients receiving sorafenib both before and after transplantation (group C; n 5 26), and patients receiving sorafenib neither before nor after transplantation (group D; n 5 50). The patient and transplant characteristics were similar among the 4 groups (all P values > .05; Table 1 ).
GVHD
Ninety-two patients developed aGVHD (grade I, n 5 39; grade II, n 5 35; grade III, n 5 14; grade IV, n 5 4), and they included 22 cases after a donor lymphocyte infusion (DLI). After we had ruled out the effects of DLIs, the cumulative incidences of overall and grade III to IV aGVHD by day 1100 were 48.6% 6 4.2% and 9.7% 6 2.5%, respectively. The incidence of aGVHD did not differ significantly among the 4 groups (P 5 .146), but it was higher for the patients receiving sorafenib maintenance after transplantation versus those without maintenance after transplantation (59.6% 6 6.5% vs 41.9% 6 5.4%; P 5 .041). Sixty-one of the 136 patients surviving more than 100 days developed chronic graft-versus-host disease (cGVHD; local, n 5 45; extensive, n 5 16), and they included 16 cases after a DLI. The cumulative incidences of overall and extensive cGVHD at 2 years were 49.2% 6 4.6% and 14.6% 6 3.5%, respectively. The incidences of overall and extensive cGVHD were similar among the 4 groups (P 5 .164 and P 5 .207, respectively). The incidence of cGVHD was not significantly different for patients with and without sorafenib maintenance after transplantation (P 5 .818).
Relapse
With a median time of 142 days after transplantation (range, 44-589 days), 40 patients experienced leukemia relapse. Two patients relapsed during sorafenib maintenance after transplantation. Thirty-four of the 40 patients had FLT3-ITD mutations at the time of relapse, whereas the other 6 patients had the FLT3-ITD wild type. None of the 40 patients acquired FLT3-TKD mutations. The 1-and 3-year cumulative incidences of leukemia relapse were 24.3% 6 6.2% and 28.7% 6 10.6%, respectively. The 3-year Original Article cumulative relapse rates were 22.2% 6 8.3%, 18.8% 6 3.1%, 15.8% 6 3.8%, and 46.1% 6 19.1% for groups A, B, C, and D, respectively (P 5 .006; Fig. 1A ). The relapse rate in group D was higher than the rates in groups A, B, and C (P 5 .025, P 5 .007, and P 5 .004, respectively). There was no significant difference in the relapse rates for groups A, B, and C (P > .05 only risk factor for a lower relapse rate (HR, 2.327 [P 5
.022]; Table 2 ). Of the 40 relapsed patients, 32 received salvage therapy, and 8 abandoned treatment. Except for 2 patients who relapsed during sorafenib maintenance after transplantation and were treated with chemotherapy combined with a DLI, these patients (n 5 30) received salvage therapy containing sorafenib, regardless of whether they were positive for an FLT3-ITD mutation at relapse. Twentyseven of the 30 patients received chemotherapy combined with sorafenib and a DLI; 3 received only chemotherapy combined with sorafenib without a DLI because of grade II or higher aGVHD or extensive cGVHD at relapse. Among the 32 patients receiving salvage treatment, 16 achieved a CR and 3 achieved a PR after salvage treatment. Eleven CR patients became FLT3-ITD-negative according to PCR in the bone marrow; this was complete molecular remission. Of the 30 patients undergoing salvage therapy with sorafenib, 11 had received sorafenib before relapse, and 19 had not. The CR rates for salvage therapy were 54.5% (6 of 11) and 52.6% (10 of 19) for the patients with and without prior exposure to sorafenib before relapse, respectively (P 5 .919). A total of 36 DLI doses were administered to the 29 patients undergoing salvage therapy containing a DLI, which was given a median of 1.2 times per patient (range, 1-3) at a median dosage of 3.1 3 10 7 CD31 T cells/kg (range, 1.5-6.5 3 10 7 CD31 T cells/kg). Fourteen patients developed aGVHD (grade I, n 5 5; grade II, n 5 6; grade III, n 5 2; grade IV, n 5 1), 7 developed cGVHD (local, n 5 5; extensive, n 5 2), and 1 died of aGVHD after DLI. With a median follow-up of 389 days (range, 53-1347 days) after posttransplant relapse, 12 patients remained alive with a CR; this meant an OS rate of 29.2% 6 9.2% 1 year after relapse.
Survival
With a median follow-up of 707 days (range, 38-1959 days) after transplantation, 101 patients survived, and 43 died. The causes of death included leukemia progression (n 5 1), leukemia relapse (n 5 25), infections (n 5 10), GVHD (n 5 5), gastrointestinal hemorrhage (n 5 1), and acute left ventricular failure (n 5 1). The 3-year NRM rate after transplantation was 12.8% 6 8.8%, and NRM was similar among the 4 groups (P 5 .181; Fig.  1B ). The 3-year OS and LFS rates were 68.4% 6 4.1% and 60.7% 6 4.2%, respectively. The 3-year OS and LFS rates were 74.9% 6 7.2% and 69.4% 6 7.7%, respectively, in group A, 78.1% 6 7.3% and 78.1% 6 7.3%, respectively, in group B, 84.6% 6 7.1% and 80.4% 6 7.9%, respectively, in group C, and 50.9% 6 7.6% and 34.8% 6 7.0%, respectively, in group D (P 5 .023 and P < .001, respectively; Fig. 2A,B) . LFS in group D was shorter than that in groups A, B, and C (P 5 .007, P < .001, and P < .001, respectively). OS in group D was shorter than that in group C (P 5 .012), but it was similar to that in groups A and B (P 5 .088 and P 5 .072, respectively). There were no significant differences in OS or LFS among groups A, B, and C (all P values > .05). A multivariate analysis revealed that sorafenib before transplantation, sorafenib maintenance after transplantation, and their combined application were all protective factors for Table 2 ).
Safety and Tolerability of Sorafenib Therapy
The most common AEs of sorafenib were cytopenias and skin rashes. 18 To exclude the effects of cytopenias caused by sorafenib combined with chemotherapy, we analyzed only the effect of sorafenib as maintenance therapy on a hemogram. During the 120 episodes of sorafenib maintenance therapy (62 before transplantation and 58 after transplantation), 55 patients experienced cytopenias, including 22 cases of leukopenia, 13 cases of thrombocytopenia, 6 cases of anemia, 9 cases of leukopenia along with thrombocytopenia, and 5 cases of pancytopenia. None of the patients discontinued sorafenib because of grade IV cytopenias. The overlap in skin rashes between a sorafenib AE and GVHD is a difficulty for the differential diagnosis. In this study, grade II or higher aGVHD-like manifestations were considered aGVHD, and sorafenib was discontinued immediately. If patients developed grade I aGVHD-like manifestations, sorafenib was reduced/discontinued at the onset of these symptoms, and anti-allergy therapy was given. A skin rash was considered aGVHD if the symptom progressed after 3 days' treatment or did not improve after 7 days' treatment. Otherwise, it was considered a sorafenib AE. Of the 113 patients receiving sorafenib therapy, 44 experienced 51 episodes of skin rash; they included 37 cases with 1 episode and 7 cases with 2 episodes. As for the 51 episodes of skin rash, 6 patients developed a skin rash before transplantation, 31 developed a skin rash after transplantation, and 7 developed skin rashes both before and after transplantation. The incidence of skin rash was lower for the patients receiving sorafenib before transplantation in comparison with those receiving sorafenib after transplantation (13 of 62 vs 38 of 85; P 5 .003). The skin rash gradually healed after the reduction/discontinuation of sorafenib in all 13 patients receiving sorafenib before transplantation. Of the 38 patients who developed an aGVHD-like skin rash during sorafenib treatment after transplantation, 11 required the use of a glucocorticoid after the reduction/discontinuation of sorafenib. Their skin rashes faded gradually and were considered aGVHD (grade I, n 5 6; grade II, n 5 5). With the 11 aforementioned patients excluded, patients receiving sorafenib before transplantation also had a lower incidence of skin rash than those receiving sorafenib after transplantation (13 of 62 vs 27 of 74; P 5 .048). Sorafenib therapy was restarted at the same or reduced dose in all patients discontinuing sorafenib because of suspected toxicity.
DISCUSSION
Several FLT3 tyrosine kinase inhibitors (TKIs), including sorafenib, midostaurin, and lestaurtinib, have been explored in various settings for FLT3-ITD AML, including induction, postremission maintenance before transplantation, maintenance after transplantation, and salvage therapy for relapsed patients. 13, 19, 20 Recently, midostaurin has been approved for the treatment of newly diagnosed FLT3-mutated AML in combination with chemotherapy. A phase 2 randomized trial of midostaurin as maintenance after hematopoietic stem cell transplantation (NCT01883362) is ongoing, and the results are eagerly awaited. Sorafenib has been extensively used over the last decade as therapy for patients with FLT3-ITD AML who have been unable to participate in trials of other FLT3 TKIs. A growing body of clinical evidence indicates that whether sorafenib is used before or after transplantation, sorafenib in combination with allo-HSCT might benefit patients with FLT3-ITD AML. [10] [11] [12] [13] [14] However, these studies had small samples, and to our knowledge, there is a lack of comparative studies on the efficacy of sorafenib therapy before and after transplantation. In this large-sample, retrospective study, we compared the effects of sorafenib at different time points on the outcomes of patients with FLT3-ITD AML undergoing allo-HSCT. Our results demonstrated that sorafenib therapy before transplantation, maintenance after transplantation, and their combined application all could reduce the relapse rate and improve LFS for patients with FLT3-ITD AML in comparison with those not using sorafenib. However, there were no significant differences in the relapse rates or LFS among groups A, B, and C. Notably, OS in group C was longer than that in group D, but it was similar to that in groups A and B. There was also no statistical difference in OS among groups A, B, and D, with 3-year OS rates of 74.9%, 78.1%, 84.6%, and 50.9% in groups A, B, C, and D, respectively. This result might be attributed to the higher CR rate and longer survival associated with salvage therapy for our patients who relapsed after transplantation. We also could not rule out the possibility that a difference might be found among the 4 groups if the sample size were enlarged. On the basis of these results, further study is needed to determine whether using sorafenib both before transplantation and as maintenance after transplantation might be ideal. To further verify the effect of sorafenib therapy on the outcomes of patients with FLT3-ITD AML undergoing allo-HSCT, we designed a prospective, randomized, multicenter clinical trial (NCT02474290), which has been conducted since 2015.
The therapeutic efficacy of allo-HSCT relies on the graft-versus-leukemia (GVL) reaction to some extent. Generally, the occurrence of GVHD is considered to be associated with GVL. Recent studies have demonstrated that sorafenib might synergize with allogeneic immune effects to enhance the GVL reaction. 21, 22 Skin is the most frequently involved organ in GVHD, and a skin rash is also the main AE of sorafenib. One challenge of diagnosis is to distinguish skin rashes caused by a sorafenib AE and GVHD. In this study, we compared the incidence of skin rashes in the patients receiving sorafenib before and after transplantation. Interestingly, we found that the incidence of skin rashes was higher in the patients receiving sorafenib after transplantation versus those receiving sorafenib before transplantation. Can a skin rash be attributed to a sorafenib AE or GVHD? Antar et al 22 reported that biopsy-proven skin aGVHD was observed in 5 of 6 patients who received sorafenib after transplantation, and it occurred within a few days of the initiation of sorafenib. It was a pity that we did not conduct biopsies for skin rashes. We distinguished between a sorafenib AE and GVHD on the basis of the severity of the skin rash and the therapeutic response. After we had ruled out the effects of aGVHD, patients receiving sorafenib after transplantation had a higher incidence of skin rashes than those receiving sorafenib before transplantation. Meanwhile, ruling out the effects of an sorafenib AE, we found that the incidence of aGVHD in the patients receiving sorafenib maintenance after transplantation was higher than those without maintenance after transplantation. These results suggested that the use of sorafenib after transplantation might enhance the GVL effect.
Leukemia relapse after allo-HSCT remains a major obstacle for long survival. Current treatment strategies are limited for these cohorts and include chemotherapy, DLIs, allo-HSCT for a second time, and targeted drugs. 23 For patients with AML with the FLT3-ITD wild type who relapsed after allo-HSCT, the CR rate was approximately 15% to 29%. 24, 25 Before the era of FLT3 TKIs, the prognosis of patients with FLT3-ITD AML who relapsed after allo-HSCT was dismal, and it was improved to a certain extent with the emergence of FLT3 TKIs. Several reports documented that sorafenib administration to patients with FLT3-ITD who had relapsed after transplantation could induce sustained responses. 21, 26, 27 Metzelder et al 21, 27 reported that sorafenib monotherapy resulted in a 48% CR rate and a 21% long-term survival rate for 29 patients with FLT3-ITD who had relapsed after transplantation. De Freitas et al 26 demonstrated that among 13 patients who had relapsed after allo-HSCT and were treated with sorafenib alone or in combination with hypomethylating agents and adoptive immunotherapy, 6 cases continued to have a CR after a median follow-up of 175 days with a 1-year OS rate after relapse of 22%. In this study, salvage therapy with chemotherapy combined with sorafenib and a DLI was used for patients with FLT3-ITD AML who had relapsed after transplantation. The CR and OS rates 1 year after relapse were 50.0% and 29.2%, respectively. Our CR rate was similar to that reported in the related literature, but survival was better. 21, 26, 27 This might be attributed to sorafenib, in combination with chemotherapy and a DLI, inducing an enhancement of the GVL effect.
Recently, a few studies suggested that long-term exposure to sorafenib could induce secondary point mutations and result in drug resistance, which was the primary cause of sorafenib treatment failure. 28, 29 However, our results showed that patients with and without prior exposure to sorafenib experienced the same efficacy with salvage therapy containing sorafenib. Metzelder et al 21 reported that of 3 patients who relapsed after transplantation and had received sorafenib before allo-HSCT, 2 achieved a CR after salvage treatment with sorafenib monotherapy. Unfortunately, we did not detect the drugresistance mutations for these patients. Among the 40 patients who relapsed after transplantation, 34 had FLT3-ITD mutations, 6 had the FLT3-ITD wild type, and none had acquired FLT3-TKD mutations at the time of relapse. Whether sorafenib combined with chemotherapy and a DLI could reverse drug resistance is worthy of further study.
In conclusion, sorafenib therapy before transplantation, sorafenib maintenance after transplantation, and their combined application all could improve the outcomes of patients with FLT3-ITD AML. Further study is needed to determine whether the use of sorafenib both before transplantation and as maintenance after transplantation might be ideal. 
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